22 August 2014
Abzena’s subsidiary Antitope and University College London enter into Research & Licence Agreement
Abzena’s subsidiary Antitope and University College London enter into a Research & Licence Agreement for the generation of fully humanized antibodies using Antitope’s Composite Human Antibody™ technology … Cambridge, UK – Abzena plc (AIM: ABZA or...
6 August 2014
Biofortuna expands freeze dried production service
Biofortuna Ltd, a UK-based molecular diagnostics company, announces significant expansion of its freeze dried (lyophilization) production service. Due to an increased demand of companies outsourcing their freeze-dried production of diagnostic kits, Biofortuna has invested in a...
9 July 2014
Oxford BioTherapeutics Appoints Eugen Leo MD PhD MBA as Head of Clinical Development
OXFORD, UK and SAN JOSE, CA – 8 July 2014 – Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced today the appointment of Eugen Leo, MD, PhD...
7 July 2014
Abzena raises £20 Million in connection with forthcoming admission to AIM
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR THE COMMONWEALTH OF AUSTRALIA … London, UK – Abzena plc (“Abzena”, the “Group” or the...
25 June 2014
Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer
OXFORD, UK and SAN JOSE, CA – 18 June 2014 – Portfolio company Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced today the appointment of Dr...
29 May 2014
New class of coagulant gets go ahead for clinical trial
Haemostatix Ltd announced today that it has received authorisation from the UK regulator, MHRA, to commence a clinical trial of its lead product, PeproStat™. PeproStat is the first of a new class of peptide-based coagulant, or “haemostat”, designed to control...
23 May 2014
PolyTherics and Antitope form Abzena
New Company Created to be Leading Provider of Technologies and Services to Enable Better Biopharmaceuticals … • PolyTherics and Antitope to continue to trade as wholly owned subsidiaries of Abzena … • New brand highlights depth and range of offering to the global...
20 May 2014
Oxford Cryosystems Wins Export Award category at Made in England Awards 2014
Catapult portfolio business, Oxford Cryosystems, has been named as the winner of the Export Award category at the 2014 Made in England Awards. The awards, sponsored by Grant Thornton and held in association with South East Midlands Local Enterprise Partnership (SEMLEP)...
7 May 2014
Oxford BioTherapeutics Secures Exclusive Global Rights From Amgen and ImmunoG
Oxford BioTherapeutics Takes Exclusive Rights to Use Amgen Xenomouse® Antibodies and ImmunoGen Technology to Develop Novel Antibody-Drug Conjugate for HER2-Negative Breast Cancer … OXFORD, UK and SAN JOSE, CA – 7 May 2014 – Oxford BioTherapeutics, an...
16 April 2014
Critical Pharmaceuticals announces US patent allowance
Critical Pharmaceuticals has announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application directed towards the Company's CP024 Intranasal Growth Hormone and CP046 Intranasal Teriparatide (parathyroid hormone 1-34)...